Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial Meeting Abstract
| Authors: | Lyman, S. K.; Gordon, J.; DuPage, A.; Pramanik, P.; Howng, B.; Winter, M. B.; Popova, I. K.; Vasiljeva, O.; Jones, J.; Wong, K.; Singson, V.; Richardson, J.; Zheng, B.; Stroh, M.; Carman, L.; Huels, V.; Autio, K.; Boni, V.; Cho, D.; Garcia-Corbacho, J.; Ruiz, I. V.; Hamid, O.; Uboha, N.; de Vries, E.; El-Khoueiry, A.; Spira, A.; Sanborn, R.; Thistlethwaite, F.; Arkenau, H. T.; Bendell, J.; Ott. P.; Rizvi, N.; Will, M.; Kavanaugh, W. M.; Naing, A.; Desnoyers, L. R. |
| Abstract Title: | Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial |
| Meeting Title: | 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 6 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Nov 7-11 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2018-11-06 |
| Start Page: | 114 |
| Language: | English |
| PMCID: | PMC6220480 |
| PUBMED: | 30400835 |
| DOI: | 10.1186/s40425-018-0422-y |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P87 |
